On earnings calls with investors, executives reiterated opposition to legislation advanced by Democrats that would curtail their pricing power in the U.S.

The deals hands Amgen a few clinical programs and a marketed therapy in Tavneos, which was approved last year to treat a group of autoimmune diseases.

Spun out of a Boston Children’s research lab, the biotech is the first to emerge from a partnership ElevateBio and the hospital struck to create new cell and gene therapy companies.

The Danish drugmaker lost tens of billions in market value after revealing a key clinical study for Wegovy won't be stopped early and production issues are still being ironed out.

The biotech company secured a valuable interchangeable designation for the copycat medicine, which it plans to launch later this year.

Together, the biotech’s two CAR-T therapies earned $368 million between April and June, a substantial jump over last year and above what analysts forecast.

The pharma has now signed two alliances with allogeneic drug developers since September, signalling its interest in CAR-T treatment alternatives.

One week after striking a deal with Versant, the antibody specialist is teaming up with Atlas to provide drug candidates to an undisclosed startup backed by the biotech investor.

The success of Alnylam's treatment in a trial known as APOLLO-B could pave the way for the biotech to reach consistent profitability, should the FDA sign off on a planned approval application.

The pharma claimed Phase 3 study success for a subcutaneous version of its drug Tecentriq, a strategy it and rivals Merck and Bristol Myers could use to extend the market life of their lucrative drugs.

Founded by serial entrepreneur Alexis Borisy, the company comes equipped with two experimental medicines it licensed from Merck KGaA and Blueprint Medicines.

It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.